Compare Bristol-Myers Squibb Co (BMY) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Quantumscape Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.64 (market cap $116.30B), while Quantumscape Corp trades at $6.61 (market cap $3.95B). The key difference: Bristol-Myers Squibb Co is far larger — about 29.4× Quantumscape Corp's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| BMY | QS | |
|---|---|---|
Market Cap | $116.30B | $3.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $18.44 |
52-Week Low | $42.60 | $5.96 |
Enterprise Value | $152.24B | $3.11B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QuantumScape (QS) trades at $6.28, down 4.56% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05M in 2025 and relies on financing cash flows to fund operations. Recent news highlights a joint research agreement with Honda, providing a potential catalyst for its solid-state battery technology development.
The outlook remains speculative with high execution risks as QS transitions from R&D to commercialization. Analyst sentiment is cautious with 73% hold ratings. Investment opportunity hinges on successful battery commercialization, but risks include persistent losses, competitive threats, and reliance on external funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
